Cell Biotech Co., Ltd. (KOSDAQ:049960)
South Korea
· Delayed Price · Currency is KRW 16,230
+30 (0.19%)
At close: Apr 29, 2026
Cell Biotech Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 10,125 | 15,127 | 6,304 | 8,281 | 10,383 | Upgrade
|
| Depreciation & Amortization | 3,614 | 3,872 | 3,904 | 3,638 | 3,789 | Upgrade
|
| Loss (Gain) From Sale of Assets | 108.08 | -10.14 | 82.45 | 0.91 | -29.05 | Upgrade
|
| Loss (Gain) From Sale of Investments | -868.86 | -575.56 | 211.19 | - | -111.68 | Upgrade
|
| Provision & Write-off of Bad Debts | 8.95 | 1.44 | -0.1 | -0.39 | -0.44 | Upgrade
|
| Other Operating Activities | -1,336 | 167.48 | -215.9 | 154.35 | 441.37 | Upgrade
|
| Change in Accounts Receivable | -140.62 | 817.31 | 51.01 | 39.38 | 144.48 | Upgrade
|
| Change in Inventory | -412.51 | -81.6 | -19.33 | -506.84 | -79.79 | Upgrade
|
| Change in Accounts Payable | -504.21 | 38.76 | -875.33 | 96.3 | 271.08 | Upgrade
|
| Change in Unearned Revenue | 5.7 | 0.54 | -3.86 | -19.54 | 8.92 | Upgrade
|
| Change in Income Taxes | - | - | -643.39 | - | - | Upgrade
|
| Change in Other Net Operating Assets | 509.17 | -90.03 | -979.12 | 1,131 | 74.98 | Upgrade
|
| Operating Cash Flow | 11,109 | 19,267 | 7,815 | 12,814 | 14,892 | Upgrade
|
| Operating Cash Flow Growth | -42.34% | 146.53% | -39.01% | -13.96% | 55.71% | Upgrade
|
| Capital Expenditures | -3,105 | -1,129 | -1,552 | -2,368 | -848.59 | Upgrade
|
| Sale of Property, Plant & Equipment | 63.48 | 79.5 | 0 | 1.7 | 16.77 | Upgrade
|
| Sale (Purchase) of Intangibles | 2.14 | -113.83 | -123.92 | -304.2 | 25.86 | Upgrade
|
| Sale (Purchase) of Real Estate | - | - | - | - | 14.92 | Upgrade
|
| Investment in Securities | 7,562 | -17,685 | -3,062 | -4,138 | -10,499 | Upgrade
|
| Other Investing Activities | 32.73 | 213.05 | 12.17 | 38.62 | 2.6 | Upgrade
|
| Investing Cash Flow | 4,590 | -18,737 | -4,745 | -6,669 | -11,132 | Upgrade
|
| Long-Term Debt Repaid | -612.73 | -661.5 | -641.07 | -636.49 | -676.15 | Upgrade
|
| Net Debt Issued (Repaid) | -612.73 | -661.5 | -641.07 | -636.49 | -676.15 | Upgrade
|
| Repurchase of Common Stock | - | - | - | -3,719 | - | Upgrade
|
| Dividends Paid | -3,080 | -3,080 | -3,080 | -3,182 | -3,182 | Upgrade
|
| Financing Cash Flow | -3,692 | -3,741 | -3,721 | -7,538 | -3,858 | Upgrade
|
| Foreign Exchange Rate Adjustments | 375.56 | 83.65 | 76.91 | -9.33 | 357.88 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | - | 0 | -0 | - | Upgrade
|
| Net Cash Flow | 12,382 | -3,128 | -573.48 | -1,402 | 260.35 | Upgrade
|
| Free Cash Flow | 8,004 | 18,138 | 6,264 | 10,445 | 14,044 | Upgrade
|
| Free Cash Flow Growth | -55.87% | 189.57% | -40.03% | -25.62% | 116.55% | Upgrade
|
| Free Cash Flow Margin | 15.07% | 36.34% | 11.65% | 20.67% | 29.96% | Upgrade
|
| Free Cash Flow Per Share | 1169.23 | 2649.95 | 915.24 | 1515.03 | 1985.94 | Upgrade
|
| Cash Interest Paid | 32.59 | 60.88 | 61.95 | 37.49 | 42.48 | Upgrade
|
| Cash Income Tax Paid | 2,423 | -1,539 | 1,355 | 1,371 | -136.75 | Upgrade
|
| Levered Free Cash Flow | 3,780 | 9,753 | -335.57 | 5,547 | 9,207 | Upgrade
|
| Unlevered Free Cash Flow | 3,800 | 9,791 | -296.85 | 5,571 | 9,233 | Upgrade
|
| Change in Working Capital | -542.47 | 684.99 | -2,470 | 740.73 | 419.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.